Please use this identifier to cite or link to this item:
|Title:||High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics|
|Authors:||Santamaría, Carlos; Chillón, Maria del Carmen; García-Sanz, Ramón; Caballero, Dolores; Sarasquete, María Eugenia; Díaz-Mediavilla, J.; San Miguel, Jesús F.; González, Marcos|
|Citation:||Leukemia Research 33(12): 1706-1709 (2009)|
|Abstract:||The PI3/AKT pathway is up-regulated in acute myeloid leukemia (AML), but its prognostic relevance in cytogenetically normal AML (CN-AML) is unclear. We evaluated RNA levels of AKT and two downstream substrates (FOXO3a-p27) in 110 de novo CN-AML, included in the Spanish PETHEMA therapeutic protocols. Patients with high FOXO3a gene expression displayed shorter OS (p = 0.015) and RFS (p = 0.048) than low FOXO3a expressers. Features selected in the multivariate analysis as having an independent prognostic value for a shorter survival were WBC > 50 × 109/L, age >65 years and high FOXO3a expression. We concluded that FOXO3a assessment could contribute to improve the molecular-based risk stratification in CN-AML. © 2009 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||(IBMCC) Artículos|
Show full item recordCSIC SFX Links
WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.